MCINNES; Campbell
Patent Applications and Registrations
Patent applications and USPTO patent grants for MCINNES; Campbell.The latest application filed is for "3-amino-4-[4-[4 (dimethylcarbamoyl) phenyl]-1,4-diazepan-1-yl]thieno[2,3-b]pyridine-2-carboxamide for use in cancer therapy and formulations comprising the same".
- MCINNES; Campbell - Irmo SC
- McInnes; Campbell - Dundee GB
- McInnes, Campbell - Longforgan GB
| Patent | Date |
|---|---|
| 3-amino-4-[4-[4 (dimethylcarbamoyl) Phenyl]-1,4-diazepan-1-yl]thieno[2,3-b]pyridine-2-carboxamide For Use In Cancer Therapy And Formulations Comprising The Same App 20220226343 - RONINSON; Igor ; et al. | 2022-07-21 |
| Bicyclic Pyridine Compositions And Methods Of Using The Same For Cancer Therapy App 20220135583 - RONINSON; Igor B. ; et al. | 2022-05-05 |
| Design And Optimization Of Type Iv Braf Inhibitors For The Treatment Of Melanoma App 20220127585 - MCINNES; CAMPBELL ; et al. | 2022-04-28 |
| Peptide based inhibitors of Raf kinase protein dimerization and kinase activity Grant 11,162,083 - McInnes , et al. November 2, 2 | 2021-11-02 |
| Quinoline-based Compounds And Methods Of Inhibiting Cdk8/19 App 20210276956 - Roninson; Igor ; et al. | 2021-09-09 |
| Quinoline-based compounds and methods of inhibiting CDK8/19 Grant 11,014,906 - Roninson , et al. May 25, 2 | 2021-05-25 |
| Small Molecule Inhibitors Selective for Polo-Like Kinase Proteins App 20200399297 - MCINNES; CAMPBELL ; et al. | 2020-12-24 |
| Quinoline-based Compounds And Methods Of Inhibiting Cdk8/19 App 20200062728 - Roninson; Igor ; et al. | 2020-02-27 |
| Peptide Based Inhibitors of Raf Kinase Protein Dimerization and Kinase Activity App 20190382738 - MCINNES; CAMPBELL ; et al. | 2019-12-19 |
| Selective Inhibitors of the Polo-Like Kinase 1 Polo-Box Domain App 20190269784 - McInnes; Campbell | 2019-09-05 |
| Fragment ligated inhibitors selective for the polo box domain of PLK1 Grant 10,067,131 - McInnes , et al. September 4, 2 | 2018-09-04 |
| Cyclin based inhibitors of CDK2 and CDK4 Grant 9,982,015 - McInnes , et al. May 29, 2 | 2018-05-29 |
| Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins App 20170283445 - McInnes; Campbell ; et al. | 2017-10-05 |
| Cyclin Based Inhibitors Of Cdk2 And Cdk4 App 20170218018 - Mcinnes; Campbell ; et al. | 2017-08-03 |
| Cyclin based inhibitors of CDK2 and CDK4 Grant 9,376,465 - McInnes , et al. June 28, 2 | 2016-06-28 |
| Cyclin based inhibitors of CDK2 and CDK4 Grant 9,328,139 - McInnes , et al. May 3, 2 | 2016-05-03 |
| Method of Forming Fragment Ligated Inhibitors App 20160011195 - McInnes; Campbell ; et al. | 2016-01-14 |
| Fragment Ligated Inhibitors Selective for the Polo Box Domain of PLK1 App 20150315555 - McInnes; Campbell ; et al. | 2015-11-05 |
| Fragment ligated inhibitors selective for the polo box domain of PLK1 Grant 9,175,357 - McInnes , et al. November 3, 2 | 2015-11-03 |
| Cyclin Based Inhibitors of CDK2 and CDK4 App 20150011730 - McInnes; Campbell ; et al. | 2015-01-08 |
| Cyclin Based Inhibitors Of Cdk2 And Cdk4 App 20140316107 - McInnes; Campbell ; et al. | 2014-10-23 |
| Cyclin Based Inhibitors of CDK2 and CDK4 App 20140296484 - McInnes; Campbell ; et al. | 2014-10-02 |
| Cyclin Based Inhibitors of CDK2 and CDK4 App 20130289240 - McInnes; Campbell ; et al. | 2013-10-31 |
| Cyclin based inhibitors of CDK2 and CDK4 Grant 8,566,072 - McInnes , et al. October 22, 2 | 2013-10-22 |
| Fragment Ligated Inhibitors Selective for the Polo Box Domain of PLK1 App 20120202970 - McInnes; Campbell ; et al. | 2012-08-09 |
| Cyclin Based Inhibitors of CDK2 and CDK4 App 20110257365 - McInnes; Campbell ; et al. | 2011-10-20 |
| Pyrimidine compounds Grant 7,897,605 - Wang , et al. March 1, 2 | 2011-03-01 |
| 4-Heteroaryl Pyrimidine Derivatives and use thereof as Protein Kinase Inhibitors App 20090215805 - Wood; Gavin ; et al. | 2009-08-27 |
| Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases Grant 7,576,091 - McInnes , et al. August 18, 2 | 2009-08-18 |
| Pyrimidine compounds App 20080287439 - Wang; Shudong ; et al. | 2008-11-20 |
| p21 peptides Grant 7,449,544 - Zheleva , et al. November 11, 2 | 2008-11-11 |
| Pyrimidine compounds Grant 7,432,260 - Wang , et al. October 7, 2 | 2008-10-07 |
| Crystal Structure of Human Proliferating Cell Nuclear Antigen (Pcna) and Uses Thereof App 20080167385 - Kontopidis; George ; et al. | 2008-07-10 |
| Method for Identifying Inhibitors Using a Homology Model of Polo-Like Kinase 1 App 20080132484 - McInnes; Campbell ; et al. | 2008-06-05 |
| P21 derived peptides and uses thereof App 20060293245 - Zheleva; Daniella I. ; et al. | 2006-12-28 |
| Cyclin groove inhibitors App 20060281687 - Andrews; Martin J.I. ; et al. | 2006-12-14 |
| Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases App 20060264628 - McInnes; Campbell ; et al. | 2006-11-23 |
| Benzthiazole-3 oxides useful for the treatment of proliferative disorders App 20060040997 - McInnes; Campbell ; et al. | 2006-02-23 |
| Pyrimidine compounds App 20050192300 - Wang, Shudong ; et al. | 2005-09-01 |
| p21 peptides App 20040176301 - Zheleva, Daniella I. ; et al. | 2004-09-09 |
| p21 peptides App 20030036628 - Zheleva, Daniella I. ; et al. | 2003-02-20 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 